JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 51.32 Billion KRW | 6.66% |
| 2022 | 48.12 Billion KRW | -2.11% |
| 2021 | 49.15 Billion KRW | -17.38% |
| 2020 | 59.49 Billion KRW | 22.41% |
| 2019 | 48.6 Billion KRW | 23.0% |
| 2018 | 39.51 Billion KRW | 6.28% |
| 2017 | 37.18 Billion KRW | 8.46% |
| 2016 | 34.27 Billion KRW | 13.49% |
| 2015 | 30.2 Billion KRW | 22.48% |
| 2014 | 24.66 Billion KRW | 47.39% |
| 2013 | 16.73 Billion KRW | 2.13% |
| 2012 | 16.38 Billion KRW | -1.3% |
| 2011 | 16.59 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 13.88 Billion KRW | -1.46% |
| 2024 Q1 | 14.09 Billion KRW | 3.49% |
| 2023 Q2 | 13.11 Billion KRW | -3.15% |
| 2023 Q3 | 11.89 Billion KRW | -9.34% |
| 2023 Q4 | 13.61 Billion KRW | 14.54% |
| 2023 FY | 51.32 Billion KRW | 6.66% |
| 2023 Q1 | 13.54 Billion KRW | 3.89% |
| 2022 Q4 | 13.03 Billion KRW | 22.65% |
| 2022 Q1 | 11.88 Billion KRW | -3.36% |
| 2022 Q2 | 12.57 Billion KRW | 5.76% |
| 2022 Q3 | 10.62 Billion KRW | -15.46% |
| 2022 FY | 48.12 Billion KRW | -2.11% |
| 2021 Q2 | 12.98 Billion KRW | 0.8% |
| 2021 FY | 49.15 Billion KRW | -17.38% |
| 2021 Q4 | 12.3 Billion KRW | 11.88% |
| 2021 Q1 | 12.88 Billion KRW | -16.13% |
| 2021 Q3 | 10.99 Billion KRW | -15.32% |
| 2020 Q3 | 14.44 Billion KRW | -6.0% |
| 2020 FY | 59.49 Billion KRW | 22.41% |
| 2020 Q4 | 15.35 Billion KRW | 6.34% |
| 2020 Q1 | 14.33 Billion KRW | 17.88% |
| 2020 Q2 | 15.36 Billion KRW | 7.17% |
| 2019 Q3 | 12.11 Billion KRW | -3.72% |
| 2019 FY | 48.6 Billion KRW | 23.0% |
| 2019 Q4 | 12.16 Billion KRW | 0.38% |
| 2019 Q2 | 12.58 Billion KRW | 6.22% |
| 2019 Q1 | 11.84 Billion KRW | 10.35% |
| 2018 Q4 | 10.73 Billion KRW | 3.46% |
| 2018 Q3 | 10.37 Billion KRW | 0.29% |
| 2018 Q1 | 8.05 Billion KRW | -8.67% |
| 2018 FY | 39.51 Billion KRW | 6.28% |
| 2018 Q2 | 10.34 Billion KRW | 28.44% |
| 2017 Q4 | 8.82 Billion KRW | -4.32% |
| 2017 Q3 | 9.21 Billion KRW | -2.25% |
| 2017 FY | 37.18 Billion KRW | 8.46% |
| 2017 Q2 | 9.43 Billion KRW | -2.86% |
| 2017 Q1 | 9.7 Billion KRW | 25.02% |
| 2016 Q2 | 8.64 Billion KRW | -8.21% |
| 2016 Q4 | 7.76 Billion KRW | -8.02% |
| 2016 Q3 | 8.44 Billion KRW | -2.36% |
| 2016 FY | 34.27 Billion KRW | 13.49% |
| 2016 Q1 | 9.42 Billion KRW | 13.55% |
| 2015 Q4 | 8.29 Billion KRW | 25.97% |
| 2015 Q3 | 6.58 Billion KRW | -20.06% |
| 2015 FY | 30.2 Billion KRW | 22.48% |
| 2015 Q2 | 8.23 Billion KRW | 0.0% |
| 2014 FY | 24.66 Billion KRW | 47.39% |
| 2013 FY | 16.73 Billion KRW | 2.13% |
| 2012 FY | 16.38 Billion KRW | -1.3% |
| 2011 FY | 16.59 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -10.364% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 85.904% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 74.194% |
| HANDOK Inc. | 151.36 Billion KRW | 66.092% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 23.651% |
| Yuhan Corporation | 564.5 Billion KRW | 90.908% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 84.071% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -116.132% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 93.86% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 31.603% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 74.204% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -26.262% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 45.697% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 63.562% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -10.364% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -47.843% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 33.187% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 526.089% |
| JW Holdings Corporation | 446.15 Billion KRW | 88.496% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 75.27% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 92.168% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 84.71% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 34.717% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 31.783% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 28.924% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 72.078% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -10.364% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 82.609% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 92.469% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 84.71% |
| Yuhan Corporation | 564.5 Billion KRW | 90.908% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 74.569% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 27.649% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 48.171% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 84.71% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 64.82% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 70.416% |
| CKD Bio Corp. | 5.01 Billion KRW | -924.389% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 79.812% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 72.125% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 47.695% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 34.717% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 86.184% |
| Boryung Corporation | 333.26 Billion KRW | 84.6% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -2.557% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 74.204% |